Drug Interaction and Dosing in a Patient on Warfarin and Rifampin
A 55-year-old man with a mechanical mitral valve on warfarin (INR stable at 2.5) develops a prosthetic valve endocarditis caused by methicillin-susceptible Staphylococcus aureus. He is started on IV cefazolin and rifampin 300 mg PO q8h is added for biofilm activity per ID recommendation. He is also on amiodarone and omeprazole. Three days later his INR is 1.6. The team asks whether to increase warfarin.
1. Explain the interaction between rifampin and warfarin and how it explains the falling INR. What is the mechanism and time course?
Read the worked answer
Rifampin is a potent inducer of hepatic and intestinal CYP3A4 and other enzymes (and P-glycoprotein), which increases warfarin metabolism, particularly of the more potent S-enantiomer (CYP2C9) and R-enantiomer (CYP3A4). Enzyme induction develops over several days to 1-2 weeks after starting rifampin, which matches the INR fall at day 3. The INR of 1.6 in a mechanical valve patient is dangerous because subtherapeutic anticoagulation increases thromboembolic risk. The interaction is expected and will persist as long as rifampin is continued; it may take weeks to resolve after stopping rifampin.
2. How would you manage the anticoagulation? What are the alternatives and their trade-offs?
Read the worked answer
I would not simply increase warfarin without a plan, but I do need to restore therapeutic anticoagulation. Options: (1) increase warfarin dose guided by frequent INR monitoring (every 2-3 days initially) and continue rifampin; (2) switch to a low-molecular-weight heparin (e.g., enoxaparin) for the duration of rifampin therapy, which avoids the CYP interaction but requires injections and renal monitoring; (3) consider a direct oral anticoagulant-but DOACs are generally avoided in mechanical valves, and rifampin also induces P-gp/CYP3A4, reducing DOAC levels. The safest approach in a mechanical valve patient is often LMWH or carefully titrated warfarin with close INR monitoring. I would also review other interacting drugs (amiodarone inhibits CYP and can raise INR; omeprazole has minor effects).
3. What other drug interactions and monitoring issues does rifampin introduce in this regimen?
Read the worked answer
Rifampin induces CYP3A4 and can reduce levels of amiodarone (though amiodarone is also a CYP inhibitor, the net effect is complex), and it can affect omeprazole (reduced efficacy). It also induces its own metabolism and can reduce cefazolin levels modestly (not usually clinically significant). Rifampin causes orange discoloration of body fluids, hepatotoxicity (monitor LFTs), and can reduce the efficacy of hormonal contraceptives. I would monitor INR frequently, LFTs, and renal function, and ensure the patient understands the interaction and the need for consistent monitoring. I would also confirm the rifampin dose is appropriate for endocarditis (typically 300 mg q8h or 600 mg daily) and that cefazolin dosing is adequate for MSSA endocarditis (often high-dose with prolonged infusion).